Keywords: Novartis, Human Genome Sciences, Albinterferon, Mycograb, Hepatitis C, Jouleferon, Candidiasis

Novartis drops development of albinterferon and Mycograb in candidiases, taking $590 million charge

Article | 06 October 2010

Switzerland-based Novartis (NOVN: VX) and US biotech partner Human Genome Sciences (Nasdaq: HGSI) have decided to stop the further development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Human Genome Sciences

Go to company listing

Related Drugs

albinterferon

Mycograb

Jouleferon

Go to drug listing